Profile data is unavailable for this security.
About the company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
- Revenue in USD (TTM)251.02m
- Net income in USD-296.38m
- Incorporated2012
- Employees545.00
- LocationAxsome Therapeutics IncOne World Trade Center, 22Nd FloorNEW YORK 10007United StatesUSA
- Phone+1 (212) 332-3241
- Fax+1 (212) 320-0245
- Websitehttps://www.axsome.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.02bn | 7.70k | -- | -- | 18.96 | 0.809 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.19bn | 314.00 | 4,714.44 | 9.34 | 405.64 | 10.54 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.64bn | 624.00 | -- | 17.19 | 554.14 | 9.33 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.76bn | 919.00 | -- | 4.91 | -- | 9.93 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.29bn | 352.00 | 29.52 | 5.99 | 27.61 | 6.28 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Prestige Consumer Healthcare Inc | 1.13bn | 209.34m | 3.41bn | 570.00 | 16.37 | 2.06 | 14.20 | 3.03 | 4.17 | 4.17 | 22.43 | 33.22 | 0.3373 | 3.33 | 6.55 | 1,974,311.00 | 6.28 | 3.69 | 6.55 | 3.84 | 55.49 | 56.79 | 18.60 | 12.19 | 2.02 | 5.10 | 0.4052 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| Perrigo Company PLC | 4.56bn | 700.00k | 3.54bn | 9.14k | 8,224.68 | 0.7558 | 10.04 | 0.7777 | 0.0032 | -0.0585 | 33.33 | 34.39 | 0.4219 | 2.54 | 5.78 | 498,457.30 | 0.0065 | -0.1148 | 0.0074 | -0.1315 | 35.65 | 35.28 | 0.0154 | -0.2985 | 1.08 | 1.26 | 0.4645 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.75bn | 545.00 | -- | 26.01 | -- | 14.93 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 4.12bn | 253.00 | -- | 4.46 | -- | 378.88 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.25bn | 702.00 | -- | 15.91 | -- | 8.10 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 4.66bn | 550.00 | -- | -- | -- | 21.32 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.17bn | 10.00k | 4.93 | 107.24 | 4.01 | 0.8152 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Data as of Jul 02 2024. Currency figures normalised to Axsome Therapeutics Inc's reporting currency: US Dollar USD
41.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 4.49m | 9.46% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.64m | 7.66% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.76m | 5.81% |
| Fairmount Funds Management LLCas of 31 Mar 2024 | 2.36m | 4.97% |
| Deep Track Capital LPas of 31 Mar 2024 | 1.30m | 2.75% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.12m | 2.35% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 1.11m | 2.33% |
| RA Capital Management LPas of 31 Mar 2024 | 1.00m | 2.11% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 938.72k | 1.98% |
| Geode Capital Management LLCas of 31 Mar 2024 | 845.41k | 1.78% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
